摘要
目的:探讨南京地区肿瘤治疗辅助药的临床使用情况。方法:采用回顾性调查方法,对南京地区医院2012-2014年肿瘤治疗辅助药的用药金额、用药频度(DDDs)、日均费用(DDC)及排序比(B/A)进行分析。结果:2012-2014年,该地区医院肿瘤治疗辅助药的用药金额呈上升趋势。用药金额排名靠前的康莱特、消癌平、康艾注射液、艾迪注射液等用药金额与用药人次同步性较差,临床使用不合理。结论:肿瘤治疗辅助药在抗肿瘤治疗中占据重要地位,应进一步规范其临床应用,提高用药安全性和经济性。
Objective： To discuss the clinic utilization of antineoplastic adjuvant drugs in Nanjing. Methods：The drug consumption sum, defined daily doses（DDDs）, defined daily consumption（DDC） and B/A of antineoplastic adjuvant drugs in hospitals in Nanjing from 2012 to 2014 were analyzed retrospectively. Results：The consumption sum of antineoplastic adjuvant drugs showed an upward trend from 2012 to 2014. The B/A of Kanglaite, Xiaoaiping, Kangai injections, as well as Aidi injections were less than 1 and the clinic utilization of those drugs was irrational. Conclusion： Antineoplastic adjuvant drugs played an important role in cancer therapy. The utilization of antineoplastic adjuvant drugs should be further standardized to improve the safety and economy in drug use.
作者
张静
王羽
刘慧
戴惠珍
Zhang Jing;Wang Yu;Liu Hui;Dai Huizhen(Drum Tower Hospital affiliated to School of Medicine, Nanjing University, Nanjing 210008, China;Jiangsu Medicine Information Institute, Nanjing 210029, China)
出处
《中国药事》
CAS
2018年第6期823-828,共6页
Chinese Pharmaceutical Affairs
